Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995953 | 0.86 | MIF (0.40) | LMNAKMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL5414405 | 0.86 | MIF (0.40) | LMNAKMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL1039225 | 0.86 | ALOX5 (0.39) | LMNAKMT2AALDH1A1L3MBTL1APP | |
| SCHEMBL7448758 | 0.86 | KMT2A (0.39) | LMNAKMT2AALDH1A1HTTNPC1 | |
| SCHEMBL5414409 | 0.86 | MIF (0.40) | LMNAKMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL1580054 | 0.84 | LMNA (0.36) | LMNAKMT2AALDH1A1HTTCYP3A4 | |
| SCHEMBL27928707 | 0.84 | LMNA (0.36) | LMNAKMT2ACYP3A4CYP1A2APP | |
| SCHEMBL30065221 | 0.84 | L3MBTL1 (0.45) | LMNAKMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL305032 | 0.84 | L3MBTL1 (0.45) | LMNAKMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2599350 | 0.84 | LMNA (0.45) | LMNAKMT2AALDH1A1HTTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358737-B1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH S A (LU) | 2017-03-01 | — | — | EP | disclosed |
| US-9119885-B2 | RGD-containing peptidomimetics and uses thereof | STEBA BIOTECH S.A. (LU) | 2015-09-01 | — | — | US | disclosed |
| CN-102264756-B | RGD-containing peptidomimetics and uses thereof | STEBA BIOTECH N V | 2014-08-06 | — | — | CN | disclosed |
| US-20140154181-A1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH S.A. (LU) | 2014-06-05 | — | — | US | disclosed |
| US-8673270-B2 | RGD-containing peptidomimetics and uses thereof | STEBA BIOTECH S.A. (LU) | 2014-03-18 | — | — | US | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| CN-102264756-A | Rgd-containing peptidomimetics and uses thereof | — | 2011-11-30 | — | — | CN | disclosed |
| US-20110250144-A1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH N.V. (NL) | 2011-10-13 | — | — | US | disclosed |
| EP-2358737-A2 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | Steba Biotech N.V. (NL) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010046900-A2 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH N.V. (NL) | 2010-04-29 | — | — | WO | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-2038274-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| CN-101374856-A | Inhibiting tumor cell invasion, metastasis and angiogenesis | SCRIPPS RESEARCH INST (US) | 2009-02-25 | — | — | CN | disclosed |
| WO-2009005551-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008130368-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1976861-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | The Scripps Research Institute (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007064759-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6110967-A | USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250144-A1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | GRPR, PROKR1, VIP | LMNA 3703/4885KMT2A 4033/4885ALDH1A1 2304/4885 |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | CREBBP, JUN, IRF3 | LMNA 3970/4885KMT2A 929/4885ALDH1A1 3673/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | LMNA 3944/4885KMT2A 3581/4885ALDH1A1 743/4885 |
| US-20140154181-A1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | GRPR, VIP, PROKR1 | LMNA 3620/4885KMT2A 4102/4885ALDH1A1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.